NICE (UK): Avelumab plus axitinib can be used as an option for untreated advanced renal cell carcinoma (RCC) in adults, only if: i) they have a favourable-risk status,… read more.
Eating a plant-forward diet and limiting added sugars and fats as part of the EAT–Lancet planetary diet was associated with a reduced risk of chronic kidney disease (CKD),… read more.
Idorsia Ltd announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium taking place from February 2-6, 2026…. read more.
Subtle abnormalities in kidney function – even within the range considered normal – may help identify people at risk of developing chronic kidney disease. This is shown in… read more.
Sobi announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G)… read more.
Hansa Biopharma AB announced the submission of a Biologics License Application (BLA) to the FDA for imlifidase. The Company is requesting priority review of the BLA for the… read more.
Chugai and Renalys Pharma, Inc. announced positive topline results from its Phase III clinical study of sparsentan (RE 021), an orally administered dual endothelin and angiotensin II receptor… read more.
People with impaired kidney function have higher levels of Alzheimer’s biomarkers in their blood, but not an increased risk of dementia, according to a study published December 3,… read more.
The current kidney transplant waitlistingcriterion is based on a single measurement of kidney function (estimated glomerular filtration rate [eGFR] ≤20 ml/min/1.73m2) and does not consider an individual’s risk of progressing to kidney failure…. read more.
Weaning patients with acute kidney injury (AKI) from dialysis while they are still hospitalized may save them from remaining on the treatment for the rest of their lives,… read more.
NICE (UK): Sparsentan can be used as option to treat primary immunoglobulin A nephropathy (IgAN) in adults with a: i) urine protein-to-creatinine ratio (UPCR) of 85 mg/mmol or… read more.
Roche announced that the FDA has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
